123 related articles for article (PubMed ID: 23926678)
1. [Combination of transrectal 125I seeds implantation brachytherapy and intermittent hormonal therapy for locally advanced prostate cancer].
Wu HM; Lü J; Hu WL; Zhang JH; Wang W; Xiao YS; Wang NX; Ran JW; Huang XD
Zhonghua Nan Ke Xue; 2013 Jul; 19(7):617-21. PubMed ID: 23926678
[TBL] [Abstract][Full Text] [Related]
2. [Impact of neoadjuvant hormonal therapy on the permanent ¹²⁵I-seed brachytherapy for localized high-risk prostate cancer].
Zhuang HY; Xu XM; Peng T; Lin CP
Zhonghua Yi Xue Za Zhi; 2010 Dec; 90(48):3418-20. PubMed ID: 21223817
[TBL] [Abstract][Full Text] [Related]
3. [Application of neoadjuvant hormonal therapy in (125)I permanent seed implantation for prostate cancer].
Cui X; Li Q; Xu JJ; Li J; Ou TW
Zhonghua Yi Xue Za Zhi; 2012 Oct; 92(38):2710-2. PubMed ID: 23290112
[TBL] [Abstract][Full Text] [Related]
4. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
Lehrer S; Cesaretti J; Stone NN; Stock RG
BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
[TBL] [Abstract][Full Text] [Related]
5. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
[TBL] [Abstract][Full Text] [Related]
6. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
Tanaka N; Fujimoto K; Hirao Y; Asakawa I; Hasegawa M; Konishi N
Urology; 2009 Aug; 74(2):407-11. PubMed ID: 19376570
[TBL] [Abstract][Full Text] [Related]
7. [Brachytherapy of 125I implantation for localized prostate cancer (report of 41 cases)].
Bai Q; Wang Y; Kaye KW
Zhonghua Nan Ke Xue; 2004 May; 10(5):371-3. PubMed ID: 15190833
[TBL] [Abstract][Full Text] [Related]
8. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
9. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer.
Kollmeier MA; Pei X; Algur E; Yamada Y; Cox BW; Cohen GN; Zaider M; Zelefsky MJ
Brachytherapy; 2012; 11(4):271-6. PubMed ID: 22192495
[TBL] [Abstract][Full Text] [Related]
11. [Transrectal high-intensity focused ultrasound with the Sonablate 500 for the treatment of prostate cancer].
Lu J; Chen ZY; Wang W; Zhang YF; Qiu XF; Zhang LC; Hu WL; Xu WF; Ye ZQ
Zhonghua Nan Ke Xue; 2007 Nov; 13(11):1005-8. PubMed ID: 18077913
[TBL] [Abstract][Full Text] [Related]
12. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
Zebentout O; Apardian R; Beaulieu L; Harel F; Martin AG; Vigneault E
Cancer Radiother; 2010 Jun; 14(3):183-8. PubMed ID: 20418145
[TBL] [Abstract][Full Text] [Related]
13. Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.
Lilleby W; Tafjord G; Raabe NK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):933-9. PubMed ID: 22138456
[TBL] [Abstract][Full Text] [Related]
14. [Maximal androgen blockade and maximal androgen blockade combined with 125I brachytherapy for prostatic cancer].
Su Y; Yao MY; Yuan Z; Yang JJ; Liu J; Hu XN
Zhonghua Nan Ke Xue; 2003 Sep; 9(6):434-5. PubMed ID: 14574808
[TBL] [Abstract][Full Text] [Related]
15. [I125 prostate brachytherapy--short-term results of the first 150 patients in Israel].
Matzkin H; Kaver I; Stenger A; Agai R; Esna N; Merimsky O
Harefuah; 2001 Aug; 140(8):694-8, 807. PubMed ID: 11547468
[TBL] [Abstract][Full Text] [Related]
16. Permanent prostate brachytherapy for Japanese men: results from initial 100 patients with prostate cancer.
Okaneya T; Nishizawa S; Nakayama T; Kamigaito T; Hashida I; Hosaka N
Int J Urol; 2007 Jul; 14(7):602-6. PubMed ID: 17645602
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
Joseph J; Al-Qaisieh B; Ash D; Bottomley D; Carey B
BJU Int; 2004 Dec; 94(9):1235-8. PubMed ID: 15610096
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M
BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460
[TBL] [Abstract][Full Text] [Related]
20. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
